Trial Profile
An Open-labeled, Multi-Center, Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Midostaurin (Primary)
- Indications Acute myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 13 Jan 2018 Status changed from recruiting to completed.
- 08 Aug 2016 New trial record